We aim to establish inexpensive and effective cell therapy and regenerative medicine through the development of injectable cell scaffolds (ICS).

Current status of treatment for refractory comprehensive chronic limb ischemia (CLTI)

Introducing a new cell therapy trial (ICS-001)

Chair: Dr. Atsuhiko Kawamoto, Foundation for Biomedical Research and Innovation at Kobe

Speaker: Dr. Hiroshi Akabori, Department of Cardiology, Hyogo Medical University

Dr. Masahide Furukawa, Department of Plastic Surgery, Oita Oka Hospital

Dr. Yasuyuki Fujita, Foundation for Biomedical Research and Innovation at Kobe

Dr. Kenichi Yamahara, The Institute for Advanced Medical Sciences, Hyogo Medical University

For questions regarding the new angiogenic cell therapy clinical trial (ICS-001)

for CLTI and critical limb ischemia, please contact info[at]c-tex.jp

NEWS

No posts published in this language yet

Once posts are published, you’ll see them here.

MISSION & VISION

Mission

We aim to make cell therapy and regenerative medicine more accessible and become a company needed by patients around the world.

Vision

By combining the injectable cell scaffold (ICS), an academic seed, with autologous mononuclear cells containing a large number of stem cells (CD34-positive cells), we will promote development toward the practical application of angiogenesis therapy for severe lower limb ischemia using inexpensive and effective cell therapy in the medical device category.

Currently, exploratory clinical trials are underway for angiogenesis therapy using ICS for critical limb ischemia. The implementation of confirmatory clinical trials by our company is expected to lead to the early launch of ICS on the market.

Furthermore, ICS is expected to be further developed for other ischemic diseases such as intractable ulcers, myocardial infarction, and cerebral infarction, as well as for improving the engraftment of transplanted cells when used in combination with other cell sources, such as adipose stem cells used in breast augmentation surgery.

Origin of the company name

Our company name, "CellFold Inc.", comes from the injectable cell scaf fold (ICS) that we developed. Through the development of ICS, we aim to provide new cell therapies and regenerative medicines that are more affordable and effective than ever before.